IN BRIEF: Arecor notes "strong" progress in first half as hails Ogluo

Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces "strong" progress across its business in the first half of 2023 amid progress for its in-house and partnered programmes. Cash as at June 30 falls 36% to GBP8.2 million from GBP12.8 million at December 31. Hails continued roll-out of Ogluo, a glucagon prefilled autoinjector pen used as a treatment for severe hypoglycaemia in children and adults living with diabetes. Glucagon is a hormone that stimulates glucose production in the liver. Arecor expects a second phase I clinical trial on diabetes 2-focused insulin candidate AT278 to complete in the fourth quarter of 2023.

Current stock price: 210.00 pence, up 2.4% on Thursday

12-month change: down 32%

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Arecor Therape